Inve India ▾

JB Chemicals & Pharmaceuticals share price & results

JB Chemicals & Pharmaceuticals Limited· Healthcare

Results to
Mar 2026
Latest analysed call
Q4 FY26
Ownership as of
Mar 2026

Indian pharma maker of branded formulations, APIs and CDMO; a top-5 global lozenges manufacturer.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue836 ₹ crore−7.2% YoYQuarterly, as filedQuarter to Mar 2026Revenue from operations as filed.
Operating margin23.0 %−3.0 pts YoYOperating profit / revenueQuarter to Mar 2026For the quarter; a change is in percentage points.
Net profit97.0 ₹ crore−35.3% YoYQuarterly, as filedQuarter to Mar 2026Profit after tax as filed.
Return on equity19.20 %−0.8 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Mar 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin15.02 %−5.0 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)5.90 %−6.6 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Mar 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Mar 2026

Guidance

What management said, and what became of it

2 of 6 judged targets kept · 3 open · verdicts reflect calls analysed to Q4 FY26.

JB Chemicals & Pharmaceuticals Limited management guidance track record on Inve: 9 targets tracked across analysed earnings calls (2 achieved, 4 missed, 3 open).

TargetOriginal wordingSaidLatest callVerdict
Operating EBITDA Margin27% to 29% for FY26
Call transcript, Q4 FY25 · 15 May 2025		Q4 FY25Q4 FY26:Achieved a full-year FY26 adjusted EBITDA margin of 28.1%, which falls within the guided range of 27-29%.
Call transcript, Q4 FY26 · 12 May 2026		Achieved
CDMO Quarterly Run RateINR150 crore every quarter for FY26
Call transcript, Q4 FY25 · 15 May 2025		Q4 FY25Q4 FY26:Full year FY26 CDMO revenue was INR 445 crore, an average of INR 111.25 crore per quarter, missing the original INR 150 crore target and the revised INR 115-120 crore guidance.
Call transcript, Q4 FY26 · 12 May 2026		Missed
India Business GrowthDouble-digit or low teens growth in a couple of quarters
Call transcript, Q4 FY26 · 12 May 2026		Q4 FY26Q4 FY26:Management guided that achieving double-digit or low teens growth in the India business would take a couple of quarters, following the operational reset.
Call transcript, Q4 FY26 · 12 May 2026		New

Source: Inve Guidance Tracker for JB Chemicals & Pharmaceuticals Limited · to Q4 FY26

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

4 of JB Chemicals & Pharmaceuticals Limited's 9 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 6 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹2,408.9 −3.87% · −₹97.1

Last close 16 Jul 2026 · NSE · INR · Source: Inve

Performance +46.0% 1Y

₹1.6k₹1.8k₹2.0k₹2.2k₹2.4kJul 25Aug 25Oct 25Nov 25Jan 26Feb 26Apr 26May 26Jul 26Q1 FY26 — 31 Jul 2025Q3 FY26 — 19 Jan 2026Q4 FY26 — 12 May 2026

1Y: ₹1,650.1 on 15 Jul 2025 → ₹2,408.9. High ₹2,506 (15 Jul 2026), low ₹1,650.1 (15 Jul 2025).

Previous close
₹2,506
Market cap
₹38.7k Cr
52-week range
₹1,650.1 – ₹2,506
One year
+45.54%
Price to earnings (TTM to Mar 2026)
53.05×
Return on equity (TTM to Mar 2026)
19.20%

Overview

Symbol
NSE:JBCHEPHARM
Exchange
NSE
Currency
INR

What JB Chemicals & Pharmaceuticals Limited does

Based on the company's own presentations, annual report and earnings calls.

J.B. Chemicals & Pharmaceuticals Limited (JB Pharma), established in 1976, is an India-based pharmaceutical company that develops, manufactures and markets branded formulations, with particular strength in the hypertension and broader cardiovascular segment. It earns through four lines of business — domestic formulations, international formulations, contract development and manufacturing (CDMO), and active pharmaceutical ingredients (API) — selling in India and, outside India, through direct front-end operations and distributor partnerships across regulated and semi-regulated markets, with Russia and South Africa as established home markets alongside a direct presence in the UAE and the Philippines. The company also ranks among the world's top five manufacturers of medicated and herbal lozenges. Its India-based manufacturing network produces a wide range of dosage forms — tablets, capsules, liquids, injectables, lozenges, ointments, gels and creams — across facilities holding multiple global regulatory accreditations, and its domestic formulations business is driven by a therapy-focused field force.

Segments

  • Domestic Formulations
  • International Formulations
  • CDMO
  • API
Manufacturing facilities
8 (India)
Markets of presence
40+ regulated and semi-regulated markets via direct operations and distributors
Global regulatory accreditations
25+
Dosage forms produced
10
India sales team (medical reps & supervisors)
2,600+
Brands ranked among India's Top 300 (IPM)
6
Founded 1976Headquarters Mumbai, Maharashtra, IndiaEmployees 5,600 (FY2025-26) Company website

How the price took the results

close before → close after

Q4 FY26
−3.5%
12 May
Q3 FY26
+1.2%
19 Jan
Q1 FY26
−0.7%
31 Jul

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for JB Chemicals & Pharmaceuticals Limited

Free account: one company. Everything above stays public.

Write why you follow JB Chemicals & Pharmaceuticals Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse JB Chemicals & Pharmaceuticals Limited

Guides on how to read this kind of business and the numbers that matter.